In a world where 6 billion people in low to middle income countries lack access to modern biopharmaceutical medicines, Just-Evotec Biologics has developed a continuous manufacturing platform that is reducing the production cost of antibody therapeutics below $50/gram. This innovative technology is incorporated in agile, small-footprint and sustainable J.POD production facilities. The concept has been validated by biosimilar-developer Sandoz who is working in partnership with Just-Evotec Biologics to increase patient access. Our presentation will explain how our unique technologies and business model have the potential to revolutionize the lives of patients irrespective of geography.